Treatment Options for Hepatocellular Carcinoma Based on BCLC Staging

BCLC Staging System Overview

• The Barcelona Clinic Liver Cancer (BCLC) staging system should be used to guide treatment decisions for hepatocellular carcinoma (HCC), with specific therapies recommended for each stage to optimize survival outcomes, as recommended by the European Association for the Study of the Liver 1, 2
• The BCLC staging system divides HCC patients into five prognostic categories based on tumor extent, liver function, portal pressure, and clinical performance status, with BCLC 0 (Very Early Stage) characterized by a single tumor <2 cm, Child-Pugh A, and performance status 0 3
• BCLC A (Early Stage) is characterized by a single tumor ≤5 cm or up to three nodules ≤3 cm (Milan criteria), Child-Pugh A-B, and performance status 0, as defined by the American Association for the Study of Liver Diseases 1, 3
• BCLC B (Intermediate Stage) is characterized by multinodular tumors, Child-Pugh A-B, and performance status 0, with a recommended treatment of transarterial chemoembolization (TACE) 1, 2
• BCLC C (Advanced Stage) is characterized by vascular invasion and/or extrahepatic spread, Child-Pugh A-B, and performance status 1-2, with a recommended treatment of sorafenib 1
• BCLC D (End-Stage) is characterized by any tumor burden, Child-Pugh C, and performance status 3-4, with a recommended treatment of symptomatic treatment and best supportive care 1, 2

Treatment Options by BCLC Stage

• For BCLC 0 and A (Very Early and Early Stage), radical therapies such as surgical resection and liver transplantation are recommended, with 5-year survival rates between 50-75% 1, 2, 3, 4
• For BCLC B (Intermediate Stage), TACE is the standard of care, with a survival benefit of 16 to 22 months 1, 5
• For BCLC C (Advanced Stage), sorafenib is the first-line systemic therapy, with a demonstrated survival benefit of 10.7 vs 7.9 months in the SHARP trial 1
• For BCLC D (End-Stage), symptomatic treatment and best supportive care are recommended, with liver transplantation considered in highly selected patients with tumor burden within Milan criteria despite Child-Pugh C status 1, 2

Liver Remnant Calculation for Surgical Planning

• The standard future liver remnant (FLR) calculation is (Volume of FLR ÷ Total liver volume) × 100%, with minimum FLR requirements of ≥20% for normal liver, ≥30% for chronic liver disease, and ≥40% for cirrhotic liver 2, 3, 6
• Portal vein embolization (PVE) may be considered when FLR is inadequate to induce hypertrophy of the future liver remnant 3

Special Considerations and Pitfalls

• Up to one-third of patients do not fit recommendations due to advanced age, significant comorbidities, or strategic tumor location, as noted by the American Association for the Study of Liver Diseases 5, 7, 8
• Combination therapies such as TACE plus RFA or TACE plus radiotherapy may be considered in selected cases, with improved local tumor control and survival benefits 1, 7
• Bridge therapy with TACE or RFA can be used for patients awaiting liver transplantation to prevent tumor progression, as recommended by the European Association for the Study of the Liver 1
• Antiviral therapy is important for patients with HBV or HCV-related HCC to reduce the risk of postoperative decompensation and prevent late recurrence from second primary tumors, as recommended by the American Association for the Study of Liver Diseases 3

BCLC Guidelines for Hepatocellular Carcinoma Treatment

Core Principles

• The 2022 updated BCLC staging system integrates tumor burden, liver function, and performance status to guide therapeutic decisions from curative interventions to palliative care, as recommended by the European Association for the Study of the Liver (EASL) 9
• The American Association for the Study of Liver Diseases (AASLD) emphasizes portal pressure measurement for optimizing patient selection for resection 10

Diagnostic and Staging Considerations

• The ALBI grade provides improved liver functional estimation compared to Child-Pugh alone, according to the Journal of Hepatology 9
• The Child-Pugh classification is essential for treatment selection, with the ALBI grade offering additional insight 9

Treatment Approaches

• Resection is preferred for non-cirrhotic patients or selected cirrhotic patients with single lesions and no portal hypertension, as suggested by BioScience Trends 10
• Liver transplantation is an option for patients meeting Milan criteria with decompensated cirrhosis, as indicated by BioScience Trends 11
• The 5-year survival rate for patients with curative intent treatment is 40-70%, according to BioScience Trends 10

Geographic Variations and Guideline Endorsements

• The European Society for Medical Oncology (ESMO) endorses the BCLC staging system, along with EASL and AASLD, for the management of hepatocellular carcinoma 10
• The Korean guideline uses the modified UICC staging system as primary, with BCLC as complementary, reflecting regional expertise and patient populations 12
• The Asian guidelines, including those from the Japanese Society of Hepatology (JSH) and Korean associations, often adopt more aggressive surgical approaches for intermediate-stage disease, as noted in BioScience Trends and Clinical and Molecular Hepatology 12, 13

Liver Transplantation and Bridge Therapy for Hepatocellular Carcinoma within Milan Criteria in HCV‑Positive Patients

Candidate Selection and Expected Outcomes

• Liver transplantation is the first‑line treatment for patients with small multinodular HCC (≤ 3 nodules ≤ 3 cm) or a solitary tumor ≤ 5 cm who meet Milan criteria, especially when advanced cirrhosis is present.  14
• Milan criteria (single tumor ≤ 5 cm or up to 3 nodules ≤ 3 cm each) are the standard benchmark for transplant candidacy and are associated with 5‑year overall survival of 65‑78 %, comparable to non‑oncologic transplant indications.  [15][14]
• When Milan criteria are fulfilled, transplantation provides the unique benefit of curing both the tumor and the underlying cirrhosis, with tumor‑recurrence rates < 15 % at 5 years.  [14][16]

Bridge (Neoadjuvant) Therapy While Awaiting Transplant

• Bridge therapy with local ablation (preferably radiofrequency ablation, RFA) or trans‑arterial chemo‑embolization (TACE) is recommended when the anticipated waiting time exceeds 6 months, to prevent tumor progression and lower the risk of drop‑out from the transplant list.  [15][17]14
• RFA achieves higher complete‑necrosis rates (approximately 12‑55 %) than TACE (22‑29 %), making RFA the preferred bridge modality.  [15][17]
• Observational studies suggest that neoadjuvant bridge therapy can reduce annual drop‑out rates from 15‑30 % to 0‑25 %; however, high‑quality randomized controlled trials are lacking, limiting the strength of evidence to low‑moderate.  [15][17]
• Cost‑effectiveness analyses indicate a net benefit of bridge therapies when waiting periods are > 6 months.  [15][17]
• Sorafenib is not recommended as a bridge therapy on the waiting list, based on pilot studies and cost‑effectiveness data.  [15][17]
• Patients whose disease progresses beyond Milan criteria during waiting should be placed on hold for consideration of alternative neoadjuvant options; those with macro‑vascular invasion or extra‑hepatic spread should be excluded from the transplant list.  [15][17]

Alternative Curative Options When Transplant Is Not Feasible

• Surgical resection may be offered to selected Child‑Pugh A patients with a solitary tumor, no clinically significant portal hypertension, and excellent functional status.  [18][16]
• Post‑resection recurrence is high, occurring in 50‑70 % of patients within 5 years, reflecting true recurrence or de‑novo HCC in the residual cirrhotic liver.  16
• When resection or transplant is not possible, local ablative techniques—RFA, percutaneous ethanol injection, or microwave ablation—are viable alternatives.  [18][16]
• RFA provides superior local tumor control compared with ethanol injection, especially for lesions larger than 2 cm.  16
• The number of lesions treated with RFA should not exceed five, and the cumulative maximum diameter should be ≤ 5 cm.  16

Monitoring During Waiting List and After Curative Treatment

• While on the transplant waiting list, patients must be monitored with serial imaging every three months, AFP measurement, MELD scoring, and surveillance for tumor progression beyond Milan criteria, macro‑vascular invasion, or extra‑hepatic spread.  [15][17]
• After curative resection, follow‑up should be performed every 3‑6 months with AFP testing and hepatic imaging for at least two years, as curative interventions may still be applicable for a minority of recurrences.  18